维普期刊资源整合服务平台（V6.5）

219篇 您的检索式：作者名="Rothenberg ML"

选中清除导出查看参考文献查看引证文献引用追踪共11页首页上一页第1页下一页末页 /11 跳转

	题名	作者	年代	出处	被引量
1	Matrix metalloproteinases biologic activity and clinical implications 显示文摘	Nelson AR Fingleton B Rothenberg ML	2000	Clin Oncol2000，18，5：	1
2	Matrix metalloproteinases:biologic activity and clinical implications显示文摘	Nelson AR Fingleton B Rothenberg ML	2000	J Clin Oncol2000，18，5：	1
3	Matrix Metalloproteinase Biologic Activity and Clinical Implications 显示文摘	Nelson BAR Fingleton BF Rothenberg ML	2000	J Clin Oncology2000，50，8：	1
4	Matrix metalloproteinase:Biologic activity and clinical implications 显示文摘	Nelson AR Fington B Rothenberg ML	2000	J Clin Oncol2000，18，5：	1
5	Pretreatment CA-125 and risk of relapse in advanced ovarian cancer显示文摘	Markman M Liu PY Rothenberg ML	2006	J Clin Oncol2006，24，9：	1
6	Matrix metalloproteinases:biologic activity and clinical implications显示文摘	Nelson AR Fingleton B Rothenberg ML	2000	Journal of Clinical Oncology2000，18，5：	1
7	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors :results of a phase I trial 显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，18：	1
8	Matrix metalloproteinases:biologic activity and clinical implication显示文摘	Nelson AR Fingleton B Rothenberg ML	2000	J Clin Oncol2000，18，5：	1
9	Matrix metalloproteinases:biologic activity and clinical implications显示文摘	Fingleton B Rothenberg ML	2000	J Clin Oncol2000，18，：	1
10	Final results of a phase Ⅲ trial of 5-Fu/leucovofin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan,5-Fu,and leucovorin显示文摘	Rothenberg ML Oza AM Burger B	2003	Proc Am Soc Clin Oncol2003，22，3：	1
11	The continuum of care: a paradigm for the management of metastatic colorectal cancer显示文摘	Goldberg RM Rothenberg ML Van Cutsem E	2007	Oncologist2007，12，1：	1
12	Matrix metalloproteinases: biologle activity and clinical implication显示文摘	Nelson AR Fingleton B Rothenberg ML	2000	J Clin Oncol2000，18，：	1
13	Superiority of ox- aliplatin and fluorouracil-leueovorin compared with either therapy alone in patients with progression eolorectal cancer after irinotecan and fluorouracil-leueovorin: interim results of a phase III trial显示文摘	Rothenberg ML Oza AM Bigelow RH	2003	J Clin Oncol2003，21，4：	1
14	Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel 显示文摘	Rothenberg ML Meropol NJ Poplin EA	2001	J Clin Oncol2001，19，18：	1
15	Matrixmetalloproteinases : biologic activity and clinical implications显示文摘	Nelson AR Fingleton B Rothenberg ML	2000	J Clin Oncol2000，18，：	1
16	Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel显示文摘	Rothenberg ML Meropol N J Poplin EA	2001	J Clin Oncol2001，19，18：	1
17	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non- small cell lung cancer and other solidtumors: results of a phase I trial显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，38：	1
18	Matrix metallproteinases: biological activity and clinical implications显示文摘	Nelson AR Fingleton B Rothenberg ML	2000	J Clin Oncol2000，18，5：	1
19	Chemotherapeutic advances in pancreatic cancer显示文摘	Berlin JD Rothenberg ML	2003	Curr Oncol Rep2003，5，3：	1
20	Matrix metalloproteinase:biologic activity and clinical implication 显示文摘	Nelson AR Fingleton B Rothenberg ML	2000	J Clin Oncol2000，5，：	1

返回顶部每页显示：

共11页首页上一页第1页下一页末页 /11 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示